Jia Hao Yeo

Dr. Jia Hao Yeo

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 July 2025 in International Journal of Antimicrobial Agents
Verified
Journal Article
Closed access
YLYang Liu
Yang Liu
STShuhua Thong
Shuhua Thong
WMWilfried Moreira
Wilfried Moreira
JYJia Hao Yeo
Jia Hao Yeo
YZYang Zhong
Yang Zhong
AKAndrea Lay-Hoon Kwa
Andrea Lay-Hoon Kwa

22 July 2025 in Journal of Global Antimicrobial Resistance
Verified
Journal Article
Open access
YZYang Zhong
Yang Zhong
JTJocelyn Qi Min Teo
Jocelyn Qi Min Teo
HCHong Yi Chang
Hong Yi Chang
JYJia Hao Yeo
Jia Hao Yeo
STShuhua Thong
Shuhua Thong
AKAndrea Lay-Hoon Kwa
Andrea Lay-Hoon Kwa
Eravacycline (ERV), a novel tetracycline-class antibiotic, has demonstrated efficacy against carbapenem-resistant Acinetobacter baumannii (CRAB) in Europe and the United States but has not been evaluated in Singapore. The objectives of this study are to evaluate the activity of ERV against CRAB clinical isolates from Singapore and to investigate the genetic profiles of these isolates, exploring novel potential ERV resistance mechanisms through whole genome sequencing (WGS) analysis. Three hundred CRAB clinical isolates collected from Singapore General Hospital (SGH) between 2012 and 2021 were tested for their susceptibility to ERV and other antibiotics. The genomic profile, including sequence type (ST), antimicrobial resistance, and virulence factor (VF) genes of these isolates, was determined. Isolates exhibiting high ERV minimum inhibitory concentrations (MICs) were further analysed to identify potential genetic mutations associated with reducing ERV susceptibility. ERV demonstrated strong in vitro activity against CRAB, with an MIC90 of 2 µg/mL. WGS analysis revealed that the 300 CRAB isolates belonged to 23 STs, with ST2 being the predominant population and frequently harbouring intrinsic blaOXA-type β-lactamases and tetracycline-class efflux pumps (tet(B)). VF analysis shows extensive genetic diversity, with variations beyond simple presence/absence patterns. Notably, the emergence of ERV resistance (elevated MIC, and MIC > MIC90) was detected, and genetic analysis of high-MIC isolates identified novel mutations in the resistance-nodulation-cell division (RND) efflux pump genes (adeABC, adeFGH, and adeIJK) and their regulatory elements (adeS/R and adeL/N). ERV is a promising therapeutic option for managing CRAB infections in Singapore. However, the emergence of resistance mediated by novel genetic mutations highlights the need for continuous surveillance and further investigation. © 2025 The Author(s). Published by Elsevier Ltd on behalf of International Society for Antimicrobial Chemotherapy.

24 June 2024 in PLOS ONE
Verified
Journal Article
Open access
PDF file
JYJia Hao Yeo
Jia Hao Yeo
JLJia Qian Low
Jia Qian Low
NBNasren Begam
Nasren Begam
WLWan-Ting Leow
Wan-Ting Leow
AKAndrea Lay-Hoon Kwa
Andrea Lay-Hoon Kwa
Current antimicrobial susceptibility testing (AST) requires 16–24 hours, delaying initiation of appropriate antibiotics. Hence, there is a need for rapid AST. This study aims to develop and evaluate the feasibility of a rapid flow cytometric AST assay to determine minimum inhibitory concentration (MIC) for carbapenem-resistant Acinetobacter baumannii (CRAB). Antibiotic exposure causes increased intracellular reactive oxygen species (ROS) in bacteria. We hypothesized that ROS can be used as a marker to determine MIC. We assessed three CRAB clinical isolates across fifteen antibiotics at various concentrations in a customized 96-well microtiter plate. The antibiotics assessed include amikacin, beta-lactams (ampicillin/sulbactam, aztreonam, cefepime, ceftolozane/tazobactam, doripenem, imipenem, meropenem, and piperacillin/tazobactam), levofloxacin, polymyxin B, rifampicin, trimethoprim/sulfamethoxazole, and tetracyclines (tigecycline and minocycline). These clinical CRAB isolates were assessed for ROS after antibiotic treatment. Increased ROS levels indicated by increased RedoxSensorTM Green (RSG) fluorescence intensity was assessed using flow cytometry (FCM). MIC was set as the lowest antibiotic concentration that gives a ≥1.5-fold increase in mode RSG fluorescence intensity (MICRSG). Accuracy of MICRSG was determined by comparing against microtiter broth dilution method performed under CLSI guidelines. ROS was deemed accurate in determining the MICs for β-lactams (83.3% accuracy) and trimethoprim/sulfamethoxazole (100% accuracy). In contrast, ROS is less accurate in determining MICs for levofloxacin (33.3% accuracy), rifampicin (0% accuracy), amikacin (33.3% accuracy), and tetracyclines (33.3% accuracy). Collectively, this study described an FCM-AST assay to determine antibiotic susceptibility of CRAB isolates within 5 hours, reducing turnaround time up to 19 hours.

12 May 2024 in Microorganisms
Verified
Journal Article
Open access
PDF file
JYJia Hao Yeo
Jia Hao Yeo
NBNasren Begam
Nasren Begam
WLWan Ting Leow
Wan Ting Leow
JGJia Xuan Goh
Jia Xuan Goh
YZYang Zhong
Yang Zhong
AKAndrea Lay-Hoon Kwa
Andrea Lay-Hoon Kwa
Antibiotic resistance is a global health crisis. Notably, carbapenem-resistant Enterobacterales (CRE) pose a significant clinical challenge due to the limited effective treatment options. This problem is exacerbated by persisters that develop upon antibiotic exposure. Bacteria persisters can tolerate high antibiotic doses and can cause recalcitrant infections, potentially developing further antibiotic resistance. Iron is a critical micronutrient for survival. We aimed to evaluate the utility of iron chelators, alone and in combination with antibiotics, in managing persisters. We hypothesized that iron chelators eradicate CRE persisters in vitro, when administered in combination with antibiotics. Our screening revealed three clinical isolates with bacteria persisters that resuscitated upon antibiotic removal. These isolates were treated with both meropenem and an iron chelator (deferoxamine mesylate, deferiprone or dexrazoxane) over 24 h. Against our hypothesis, bacteria persisters survived and resuscitated upon withdrawing both the antibiotic and iron chelator. Pursuing our aim, we next hypothesized that iron chelation is feasible as a post-antibiotic treatment in managing and suppressing persisters’ resuscitation. We exposed bacteria persisters to an iron chelator without antibiotics. Flow cytometric assessments revealed that iron chelators are inconsistent in suppressing persister resuscitation. Collectively, these results suggest that the iron chelation strategy may not be useful as an antibiotic adjunct to target planktonic bacteria persisters.

28 April 2020 in Metallomics
Verified
Journal Article
Closed access
PDF file
JZJianping Zhu
Jianping Zhu
JYJia Hao Yeo
Jia Hao Yeo
ABAmy A Bowyer
Amy A Bowyer
NPNicholas Proschogo
Nicholas Proschogo
Elizabeth NewElizabeth New
Elizabeth New
Lead is a heavy metal which has long been known to have toxic effects on the body. However, much remains to be learnt about the labile lead pool and cellular uptake of lead. We report here RPb1 that undergoes a 100-fold increase in fluorescence emission in the presence of Pb2+, and which can be applied to study the labile lead pool within cells. We demonstrate the capacity of RPb1 for investigating labile lead pool in DLD-1 cells and changes in labile lead during differentiation of K562 cells.

9 January 2026 in Nature Communications
Verified
Journal Article
Open access
PDF file
JCJasmine Jasmine Chung
Jasmine Jasmine Chung
YLYang Liu
Yang Liu
STShuhua Thong
Shuhua Thong
YZYang Zhong
Yang Zhong
ZCZhi Soon Chong
Zhi Soon Chong
AKAndrea Lay-Hoon Kwa
Andrea Lay-Hoon Kwa
Biofilm-related vascular graft infections (VGIs) pose major therapeutic challenges due to persistent, antibiotic-resistant bacteria often residing in retained grafts. Phage therapy offers a promising alternative treatment strategy against biofilm-associated infections, though its use remains mostly ad hoc and typically considered a last-resort intervention. We report here the treatment of a refractory, fluoroquinolone non-susceptible Pseudomonas aeruginosa VGI using a systematically planned and synergistic phage-antibiotic combination approach. Adjunctive phage therapy led to radiological improvement, as seen by reduced 18F-FDG PET/CT tracer uptake around the graft. The patient was transitioned to oral fluoroquinolone suppression therapy with no recurrence of bacteremia to-date, after a year. Our workflow led to the selection of phages that sensitized Pseudomonas aeruginosa to killing by levofloxacin and piperacillin-tazobactam. We established that this phage-driven antibiotic sensitization was due to the ability of our phages to use the MexAB-OprM efflux pump as a receptor. We also showed that our phages had potent anti-biofilm activity. We advocate a systematic, multi-pronged management strategy for refractory VGIs, including early therapeutic drug monitoring (TDM), in vitro antibiotic combination testing (iACT), and timely adjunctive phage therapy. This case illustrates the utility of individualized, strategic approaches and highlights adjunctive phage therapy’s potential in treating complex biofilm-related infections.